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Abstract - Hybrid or multimodal imaging has provided 
excellent opportunities to meet the needs inherent in the 
management of neurodegenerative diseases, especially in 
Alzheimer Disease context. PET-MRI equipment for 
simultaneous data acquisition attempts to address this 
challenge by bridging the limitations of PET-CT at the 
brain level and improving the results achieved through a 
simultaneous real-time combination of quantitative 
neurophysiological information from PET and accurate 
MRI morphological information, with greater 
radiological safety. Therefore, the PET-MRI technique 
presents high potential for diagnostic and follow-up 
studies. The aim of this review was to compile the main 
advantages related with PET-MRI along with the 
detection of the main challenges which remain to be 
resolved for a full clinical validation of the technique in 
Neuroimaging field are identified.  
 
Index Terms – Alzheimer disease, Neurodegenerative 
disease, Neuroimaging and PET-MRI 
INTRODUCTION 
Alzheimer's disease (AD) constitutes one of the most 
common neurodegenerative diseases today, with about 35 
million people worldwide being affected by this disease. It 
presents a progressive loss of associated memory and a 
significant weakening of cognitive functions with 
profound impact in clinical, social and economical areas. 
The pathogenesis of this type of disease is complex and still 
lacks a complete knowledge of its origin, development and 
remission. An early diagnosis and intervention is essential 
to control the development of disease. 
Not along ago, hybrid or multimodal imaging has 
provided excellent opportunities to meet the needs inherent 
in the management of Central Nervous System (CNS) 
diseases, especially regarding neurodegenerative diseases. 
Positron Emission Tomography-Computerized 
Tomography (PET-CT) has been successfully applied in 
clinical practice with better results when compared to the 
PET or CT alone options. However, the ability of Magnetic 
Ressonance Imaging (MRI) to obtain higher spatial 
resolution levels notably in soft tissues (a particularly 
critical factor in the context of the brain region) as well as 
the non-use of radiation made evident the need to add this 
technique as a new component to be included in a 
multimodality solution. PET-MRI equipment for 
simultaneous data acquisition attempts to address this 
challenge by bridging the limitations of PET-CT at the 
brain region and improving the results achieved through a 
real-time combination of PET quantitative 
neurohysiological information and MRI morphological 
information, with greater radiological safety. Due to these 
facts, the PET-MRI technique presents high potential for 
brain studies, although there are challenges yet to be 
addressed. 
The aim of this research is to describe, compile and 
review the existing scientific and technical contents in the 
literature about the application of the hybrid PET-MRI 
technique in Neuroimaging, more precisely in the context 
of AD. 
METHODOLOGY 
A literature review was performed, following a PICO 
methodogy with the question: "What is the role of PET-
MRI technique in the diagnosis of neurodegenerative 
diseases, specifically in context of Alzheimer's disease?". 
Based on the formulated question, key words and key 
phrases were identified for scientific database research: 
"Alzheimer", "neurodegenerative disease" "brain" and 
"PET-MRI" (in the different acronyms normally identified 
with Hybrid technique). The SCOPUSTM platform was 
used as digital repository of research. 
Authors gratefully acknowledge the funding of Project NORTE-01-
0145-FEDER-000022 - SciTech - Science and Technology for 
Competitive and Sustainable Industries, co-financed by “Programa 
Operacional Regional do Norte” (NORTE2020), through “Fundo 
Europeu de Desenvolvimento Regional” (FEDER). 
Only publications cataloged by the database as "article 
review" and published since 2010 in English language until 
February 2016 were considered. 
With the set of publications obtained, their feasibility 
was verified based on the application of the following 
exclusion criteria: possibility of access to the full version 
of the publications; verification of redundant items; 
empirical analysis of abstracts based on their relevance to 
the research question (publications concerning other body 
areas other than the brain region, relating in particular to 
unique and non-hybrid imaging modalities and research or 
preclinical publications were rejected). 
RESULTS 
Based on the methodology and the inclusion criteria 
used, a total of 60 publications were initially obtained, 
which after applying the exclusion criteria dropped to a 
final number of 41 scientific publications. The results 
obtained can be stratified into five fields of interest. 
I. PET-MRI EQUIPAMENTS - DESIGN AND COMPONENTS 
At present, there are four options of PET-MRI 
equipment available in the market, and the main 
performance parameters can be observed and compared in 
Table 1 [1]. 
II. ATTENUATION CORRECTION IN PET-MRI 
A technical challenge in hybrid imaging PET-MRI is 
the attenuation correction (AC) of PET emission images 
based on MRI data. Correction necessary for accurate 
quantification of radiotracer concentration. 
In PET-MRI imaging, AC of PET data needs to be 
performed through MRI data, which is based on proton 
density and tissue relaxation properties as opposed to CT 
information that is based on x-ray attenuation in tissues 
[2,3]. 
To this end, different methodologies may be applied 
namely the Dixon methodology or the T1-weighted MRI 
sequence of ecogradient. These rapid MRI sequence 
methods are based on measurements of proton density and 
relaxation times (T1 and T2) of specific tissues, parameters 
that are not directly convertible into PET coefficients of 
511 keV energy levels. Typically, MRI images are initially 
segmented into different classes based on tissue types, and 
later predefined linear attenuation coefficients are 
calculated for the computation of the attenuation maps 
necessary for the correction of PET images during data 
reconstruction. 
Nowadays, in brain imaging with PET-MRI, a huge 
challenge is related to the rapid transverse relaxation of the 
MRI signal. The AC of PET images requires density maps 
of the object under study from morphological information 
of MRI; however, tissues with a higher density as the case 
of the bone tissue are difficult to detect in MRI due to their 
short relaxation periods. MRI techniques, which allow 
detection of rapid decay of signal become essential for 
detection of specific tissues, especially bone tissue. A low 
proton density such as that present in bone tissue implies 
difficulties in visualizing structures and contrast with 
adjacent structures such as surrounding soft tissues and 
background [1-4]. 
TABLE 1. PERFORMANCE CHARACTERISTICS OF PET-MRI 
EQUIPMENT AVAILABLE IN THE MARKET TODAY (NEMA 
NU-2 2007) [1] 
PET 
Characteristic
s and NEMA 
NU-2 
Performances 
Philips 
Ingenuit
y 
PET/MR 
GE 
PET/CT 
Discovery 
690 (in 
Trimodalit
y Setup) 
GE 
Signa 
PET/M
R 
Siemens 
Biograp
h mMR 
PET FOV axial 18 15.7 25 25.8 
PET FOV 
transaxial 57.6 50-70 60 59.4 
MRI or CT FOV 
transaxial 
(for attenuation) 
45 CT 50 50 
Average spatial 
resolution at 1 
cm off center 
(mm FWHM) 
4.7 4.7 4.2 4.3 
Average Spatial 
resolution at 10 
cm off center 
(mm FWHM) 
5.1 5.3 5.1 5.5 
Timing 
Resolution (ps) 525 544 385 2930 
Energy 
Resolution 
(FWHM %) 
12 12.4 10.3 11.5 
Sensitivity 
(average 0 and 
10 cm) 
(cps/kBq) 
7.1 7.5 22.9 14.4 
Max NECR 
(kcps) at 
(kBq/mL) 
88.5 at  
13.7 
139.1 at  
29.0 
218 at 
17.7 
184 at 
23.1 
Scatter fraction 
at NECR peak 
(%) 
26 37 43.6 37.9 
FWHM, full width at half maximum; NECR, noise equivalent count rate; NEMA, National 
Electrical Manufacturers Association 
 
 
In a more efficient approach, the application of 
frequency coding in a radial three-dimensional (3D) 
centrifugal scheme may be a solution. Ultrashort Echo 
Time (UTE) and Zero Echo Time (ZTE) sequences in MRI 
acquisition have been reported as a possible solution for the 
visualization of bone tissue with very short T2 images, thus 
allowing AC to be at the bone level during image 
segmentation. This may possibly be enhanced by the 
combination of sequences obtained by the Dixon 
technique, obtaining AC maps like maps obtained with CT 
acquisition of CT in a PET-CT equipment. This method 
presents some disadvantages such as the long data 
acquisition times and the limitation of efficacy to larger 
field of views (FOVs), although in cerebral context this 
parameter is not so critical. [1-4]. 
All of these methods have advantages and 
disadvantages, and for this reason still there is not a 
consensus solution. The difficulty in segmentation of bone 
tissue is currently one of the main lines of investigation to 
solve the problem of AC in PET-MRI, particularly in the 
cerebral context due to the greater bone density in this 
region [5-9]. 
III. IMAGE DATA RECONSTRUCTION 
PET-MRI imaging reconstruction options available are 
identical to those used for PET-CT. Thus, reconstruction 
algorithms are based on iterative reconstruction methods 
and require data for normalization procedures, dead time 
analysis, photonic decay, AC and scattering correction for 
treatment of functional PET images, as required within the 
scope of PET-CT. An important factor to highlight is the 
possibility of PET-TOF image acquisition, since it allows 
for improved AC and scattering correction through 
calculating the difference of photonic detection in PET, the 
location of the origin of the events is more accurate along 
of the typical PET line of response (LOR). Recent studies 
(Vandenberghe et al., 2016) have identified PET-TOF 
acquisition applied in PET-MRI data acquisiton technique 
as a solution to perform a simultaneous reconstruction of 
the functional and morphological data and thus solve the 
important correction problems, although this solution 
needs validation in clinical scope [10-12]. 
 IV. PET-MRI IN CLINICAL NEUROIMAGING 
Given the advantageous characteristics of the MRI 
morphological technique and the PET physiological 
technique, it was quickly found necessary to correlate the 
two types of information to unite the best of the two 
imaging fields. The emergence of the hybrid PET-MRI 
equipment through simultaneous data acquisition of the 
brain region allowed an improvement in the co-registration 
and alignment of data, which already evident when using 
fusion techniques, but above all an enhancement of the 
results in terms of interconnection intrinsic diagnosis 
between the information provided by different PET 
radiopharmaceuticals and high contrast of brain tissues 
provided by the diversity of MRI techniques [13-21]. 
One of the inherent advantages of the PET technique 
and its associated biodistribution principle is the wide 
variety of specific radiopharmaceuticals to a given 
pathology. The main PET targets currently available in 
clinical practice can be seen in Table 2. The major PET 
radiopharmaceutical used in neurodegenerative diseases is 
18F-FDG which represents a universal neuronal and 
synaptic integrity biomarker due to its proportional 
correlation with the variations of glycolytic need of brain 
tissue; i.e., greater metabolic avidity tends to accumulate 
sugary compounds. In the case of AD, the lower uptake of 
this radiopharmaceutical in bilateral temporoparietal areas 
due to reduced accumulation of the tracer makes it 
necessary to use other options. Currently a few more PET 
radiopharmaceuticals appear in the context of AD 
intracellular plaques Beta Amyloid deposits: 18F-
Florbetapir, 18F-Florbetaben or 18F-Flutemetamol [14,22-
25]. 
All these indicators are strongly related to the 
pathology and the knowledge of their mode of relationship 
and their mechanisms of action is fundamental for the 
diagnosis and prognosis of AD in differentiation from other 
types of dementias [14-23]. 
The MRI technique is presented as the gold standard 
technique in the evaluation of neurodegenerative 
situations. The different techniques associated with this 
imaging method contribute significantly to this fact. In 
Table 2, the MRI techniques usually applied in clinical 
practice in the context of neurodegenerative diseases can 
be identified [14-23]. 
In the context of AD, data acquisition in T2-FLAIR 
(fluid-attenuated inversion) and/or T1 3D GRE images 
(gradient echo) can identify patterns of temporal atrophy 
per a given score - the so-called Scheltens score [14-23]. 
TABLE 2. CURRENT PET TARGETS AND MRI SEQUENCES 
FOR NEURODEGENERATIVE DISEASES IMAGING [14]. 
Disease Typical PET Targets Typical MRI Sequences 
Alzheimer 
disease 
Amyloid plaques and 
glucose consumption T2 FLAIR and T1 3D GRE 
FTLD Glucose consumption FLAIR and T1 3D GRE 
Vascular 
dementia Glucose consumption FLAIR, T2*/SWI and DWI 
DLB Glucose consumption FLAIR and T1 3D GRE 
Parkinson 
disease Dopamine synthesis 
T1, T2 multiplanar and 
T2*/SWI 
Atypical 
parkinsonian 
syndromes 
Glucose consumption T1, T2 multiplanar and T2*/SWI 
Huntington 
disease Glucose consumption T1, T2 and T2*/SWI 
ALS Glucose consumption T1 and T2 
CJD Glucose consumption DWI, FLAIR, T1 and T2 
3D, three-dimensional; CJD, Creutzfeldt-Jakob disease; DLB, dementia with lewy bodies; DWI, 
diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; GRE, gradient echo; 
SWI, susceptibility-weighted imaging 
 
Together, these techniques essentially provide support 
and consistent information to clinical results and non-
imaging biomarkers, as well as to exclude other 
neurodegenerative pathologies with similar clinical 
symptoms and indications (Figure 1) [14-23]. 
V. PET-MRI exam Protocols 
Unlike the usual protocols and flow of procedures in 
image acquisition with other hybrid techniques, as in the 
case of PET-CT, in PET-MRI protocols there are 
difficulties in the organization and management of the 
various moments of data acquisition mainly due to the 
unlimited number of MRI pulse sequences techniques, 
which lead to a high number of possible protocols to be 
adopted. However, it is necessary to reduce the options to 
achieve standardized procedures, not only to make possible 
data acquisition clinically relevant and comfortably for 
patients, but also to compare results between studies. 
Designing a sequential schedule of events at appropriate 
time periods is equally critical for the PET-MRI hybrid 
technique to become economically viable in a cost-
effective value context [24-28]. 
In the search for this solution, it is pointed out that, 
firstly, the choice of the ideal protocol depends on the type 
of existing PET-MRI equipment, since commercially there 
are options that provide the ability to simultaneous image 
aquisition in the same equipment, rather other options 
imply separate sequential acquisition of the two types of 
modalities through patient movement systems between 
different equipment [24-28]. 
Further, the clinical area of the study to be triggered 
also implies changes in protocols. In terms of PET-MRI 
application in neuroimaging, the choice of protocol and 
flow of procedures is more facilitated than in other fields 
of interest; for example, in PET-MRI whole body studies 
[24-28]. 
One of the improvements adjacent to PET-MRI 
technique is the possibility of evaluating three types of 
information simultaneously in a shorter time interval: 
functional metabolic information of PET, morphological 
information and functional information of the MRI - the so-
called Three-Eye Vision [6]. 
Brain PET-MRI is considered a specific imaging study 
in a limited FOV (only use of a bed position) with image 
acquisition times between 15 and 60 minutes per clinical 
indication, radiopharmaceutical applied and type of PET 
acquisition protocol (static or dynamic). 
Radiopharmaceuticals based on 18F usually have 
acquisition times of 30 minutes. These shorter temporal 
windows lead to the identification of PET-MRI as a 
potential future gold standard imaging tool in the context 
of AD [24,25,29]. 
 
FIGURE 1 - DIFFERENT IMAGIOLOGICAL PATTERNS IN PATIENTS WITH LOW COGNITIVE DEFICIENCY THROUGH PET-MRI 
STUDIES WITH APPLICATION OF 18F-FLORBETABEN, THE TOP LINE PRESENTS TRANSAXIAL PET-MRI IMAGES AND THE LOWER 
LINE CORONAL SECTIONS OF T1 IMAGES: (A) NEGATIVE PET STUDY, ILLNESS WITH TRAUMATIC CHANGES IN THE LEFT 
HYPOCAMP (CIRCLE) POSSIBLE INDICATION OF COGNITIVE DEFICIENCY; (B) NEGATIVE PET STUDY WITH HYPOCAMP ATROPHY 
(CIRCLES) AND SUBCORTICAL ASYMMETRY OF FRONTOTEMPORAL DEMENTIA; (C) PET POSITIVE STUDY, PATIENT WITH NO 
ATROPHY VISIBLE ON MRI IMAGE WITH POSSIBLE INTERMEDIATE AD LEVEL; AND (D) POSITIVE, PATIENT PET STUDY WITH 
VISIBLE ATROPHY ON MRI IMAGE WITH POSSIBLE AD LEVEL (NOTE: LEFT BRAIN APPEARS AT RIGHT) [14] 
DISCUSSION AND CONCLUSION 
Over the last few years, hybrid or multimodality 
imaging has provided excellent opportunities to meet the 
needs inherent in the management of CNS diseases, 
especially regarding neurodegenerative diseases. As a 
vector of development of the Neuroimaging area, AD has 
been extremely influenced by the results and imaging 
capabilities achieved by these techniques, in the knowledge 
of its historical progression, early diagnosis and therapeutic 
evaluation. 
PET-CT has been successfully applied in clinical 
practice with superior results to dedicated PET or CT 
options. However, the ability of MRI to obtain higher 
spatial resolution levels especially in soft tissues 
(especially critical factor in the context of the brain region) 
as well as the non-use of radiation made evident the need 
to include this technique as a new component to be 
included in a multimodality solution. 
PET-MRI equipment for simultaneous data acquisition 
attempts to address this challenge by bridging the 
limitations of PET-CT at the brain level and improving the 
results achieved through a simultaneous real-time 
combination of quantitative neurophysiological 
information from PET and accurate MRI morphological 
information, with greater radiological safety. Therefore, 
the PET-MRI technique presents high potential for 
diagnostic and follow-up studies. 
Progressive development in recent years, in terms of 
instrumentation and software for data acquisition and 
processing, has allowed the increase of soft tissue contrast 
and addition of functional information from the MRI 
trhough the blood diffusion, perfusion and oxygenation 
techniques, true multiplanar acquisition and reduced 
radiation exposure. 
Despite these advantages, several challenges arise 
whith PET-MRI, and its adoption in clinical practice has 
not yet been achieved mainly due to three major reasons: 
technical, clinical and financial problems. 
The PET-MRI solution presents itself as a recent 
solution in the market, already with some weight in 
neurosciences research and in preclinical studies, with 
opened unadressed challenges associated with the clinical 
level, still needing a complete technical evaluation and 
consequent clinical validation of its promising imaging 
characteristics. 
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